# Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases

> **NCT02862132** · NA · COMPLETED · sponsor: **Shaare Zedek Medical Center** · enrollment: 142 (actual)

## Conditions studied

- Crohn's Disease
- Ulcerative Colitis
- Inflammatory Bowel Disease

## Interventions

- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT02862132
- **Lead sponsor:** Shaare Zedek Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2022-01
- **Final completion:** 2022-01
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2022-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02862132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02862132, "Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02862132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*